A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsGuillermo Garcia‐Manero, Oliver G. Ottmann, H Salman et al.|Leukemia|2017Cited by 70
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)Claire Harrison, Vincent Ribrag, Jean‐Jacques Kiladjian et al.|Blood|2015Cited by 39
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk MyelofibrosisJean‐Jacques Kiladjian, Claire Harrison, Florian H. Heidel et al.|Blood|2014Cited by 14